Literature DB >> 25403158

Rheumatoid arthritis: Seronegative and seropositive RA: alike but different?

Sofia Ajeganova1, Tom W J Huizinga2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25403158     DOI： 10.1038/nrrheum.2014.194

Source DB:  PubMed          Journal:  Nat Rev Rheumatol        ISSN： 1759-4790            Impact factor:   20.543


× No keyword cloud information.
  10 in total

1.  Remission induction therapy with methotrexate and prednisone in patients with early rheumatoid and undifferentiated arthritis (the IMPROVED study).

Authors:  Kirsten Wevers-de Boer; Karen Visser; Lotte Heimans; H Karel Ronday; Esmeralda Molenaar; J Hans L M Groenendael; André J Peeters; Marie-Louise Westedt; Gerard Collée; Peter B J de Sonnaville; Bernard A M Grillet; Tom W J Huizinga; Cornelia F Allaart
Journal:  Ann Rheum Dis       Date:  2012-03-08       Impact factor: 19.103

2.  Autoantibodies recognizing carbamylated proteins are present in sera of patients with rheumatoid arthritis and predict joint damage.

Authors:  Jing Shi; Rachel Knevel; Parawee Suwannalai; Michael P van der Linden; George M C Janssen; Peter A van Veelen; Nivine E W Levarht; Annette H M van der Helm-van Mil; Anthony Cerami; Tom W J Huizinga; Rene E M Toes; Leendert A Trouw
Journal:  Proc Natl Acad Sci U S A       Date:  2011-10-10       Impact factor: 11.205

3.  The association of treatment response and joint damage with ACPA-status in recent-onset RA: a subanalysis of the 8-year follow-up of the BeSt study.

Authors:  M van den Broek; L Dirven; N B Klarenbeek; T H E Molenaar; K H Han; P J S M Kerstens; T W J Huizinga; B A C Dijkmans; C F Allaart
Journal:  Ann Rheum Dis       Date:  2011-11-21       Impact factor: 19.103

Review 4.  The influence of ACPA status and characteristics on the course of RA.

Authors:  Annemiek Willemze; Leendert A Trouw; René E M Toes; Tom W J Huizinga
Journal:  Nat Rev Rheumatol       Date:  2012-01-31       Impact factor: 20.543

5.  Prognosis of seronegative patients in a large prospective cohort of patients with early inflammatory arthritis.

Authors:  Lillian Barra; Janet E Pope; John E Orav; Gilles Boire; Boulos Haraoui; Carol Hitchon; Edward C Keystone; J Carter Thorne; Diane Tin; Vivian P Bykerk
Journal:  J Rheumatol       Date:  2014-10-01       Impact factor: 4.666

Review 6.  Autoimmunity in rheumatoid arthritis: different antigens--common principles.

Authors:  L A Trouw; Tom W J Huizinga; René E M Toes
Journal:  Ann Rheum Dis       Date:  2012-12-19       Impact factor: 19.103

7.  Sustained drug-free remission in rheumatoid arthritis after DAS-driven or non-DAS-driven therapy: a comparison of two cohort studies.

Authors:  Diane van der Woude; Karen Visser; Naomi B Klarenbeek; H Karel Ronday; André J Peeters; Pit J S M Kerstens; Ben A C Dijkmans; Tom W J Huizinga; Annette H M van der Helm-van Mil; Cornelia F Allaart
Journal:  Rheumatology (Oxford)       Date:  2012-02-15       Impact factor: 7.580

8.  Should we redefine treatment targets in rheumatoid arthritis? Low disease activity is sufficiently strict for patients who are anticitrullinated protein antibody-negative.

Authors:  Yvonne M R de Punder; Jos Hendrikx; Alfons A den Broeder; Elia Valls Pascual; Piet L van Riel; Jaap Fransen
Journal:  J Rheumatol       Date:  2013-06-01       Impact factor: 4.666

9.  Can anti-cyclic citrullinated peptide antibody-negative RA be subdivided into clinical subphenotypes?

Authors:  Diederik P C De Rooy; Annemiek Willemze; Bart Mertens; Tom W J Huizinga; Annette H M Van der Helm-van Mil
Journal:  Arthritis Res Ther       Date:  2011-10-27       Impact factor: 5.156

10.  ACPA-positive and ACPA-negative rheumatoid arthritis differ in their requirements for combination DMARDs and corticosteroids: secondary analysis of a randomized controlled trial.

Authors:  Seth D Seegobin; Margaret H Y Ma; Chanaka Dahanayake; Andrew P Cope; David L Scott; Cathryn M Lewis; Ian C Scott
Journal:  Arthritis Res Ther       Date:  2014-01-16       Impact factor: 5.156
  10 in total
  18 in total

Review 1.  Immune checkpoint inhibitor-induced inflammatory arthritis as a model of autoimmune arthritis.

Authors:  Laura C Cappelli; Mekha A Thomas; Clifton O Bingham; Ami A Shah; Erika Darrah
Journal:  Immunol Rev       Date:  2020-01-13       Impact factor: 12.988

Review 2.  Cardiovascular risk in patients with rheumatoid arthritis.

Authors:  Kim Lauper; Cem Gabay
Journal:  Semin Immunopathol       Date:  2017-04-28       Impact factor: 9.623

3.  Assessing improved risk prediction of rheumatoid arthritis by environmental, genetic, and metabolomic factors.

Authors:  Lilia Bouzit; Susan Malspeis; Jeffrey A Sparks; Jing Cui; Elizabeth W Karlson; Kazuki Yoshida; Karen H Costenbader
Journal:  Semin Arthritis Rheum       Date:  2021-07-10       Impact factor: 5.431

4.  The Impact of Seropositivity on Systemic Bone Loss in Rheumatoid Arthritis-A 3-Year Interim Analysis of a Longitudinal Observational Cohort Study.

Authors:  Shan-Fu Yu; Jia-Feng Chen; Ying-Chou Chen; Yu-Wei Wang; Chung-Yuan Hsu; Han-Ming Lai; Hsiao-Ru He; Chi-Hua Ko; Wen-Chan Chiu; Tien-Tsai Cheng
Journal:  Front Med (Lausanne)       Date:  2022-06-09

5.  Seronegative rheumatic arthritis has milder inflammation and bone erosion in an ultrasound study of disease-modifying anti-rheumatic drugs (DMARDs)-naïve Chinese cohort.

Authors:  Dongfang Lin; Minjing Zhao; Yanli Zhang; Ya Xie; Junyan Cao; Yunfeng Pan
Journal:  Ann Transl Med       Date:  2022-06

6.  Roles of Postdiagnosis Accumulation of Morbidities and Lifestyle Changes in Excess Total and Cause-Specific Mortality Risk in Rheumatoid Arthritis.

Authors:  Kazuki Yoshida; Tzu-Chieh Lin; Melissa Y Wei; Susan Malspeis; Su H Chu; Carlos A Camargo; Benjamin A Raby; Hyon K Choi; Sara K Tedeschi; Medha Barbhaiya; Bing Lu; Karen H Costenbader; Elizabeth W Karlson; Jeffrey A Sparks
Journal:  Arthritis Care Res (Hoboken)       Date:  2021-02       Impact factor: 4.794

7.  Patients lacking classical poor prognostic markers might also benefit from a step-down glucocorticoid bridging scheme in early rheumatoid arthritis: week 16 results from the randomized multicenter CareRA trial.

Authors:  Patrick Verschueren; Diederik De Cock; Luk Corluy; Rik Joos; Christine Langenaken; Veerle Taelman; Frank Raeman; Isabelle Ravelingien; Klaas Vandevyvere; Jan Lenaerts; Elke Geens; Piet Geusens; Johan Vanhoof; Anne Durnez; Jan Remans; Bert Vander Cruyssen; Els Van Essche; An Sileghem; Griet De Brabanter; Johan Joly; Kristien Van der Elst; Sabrina Meyfroidt; Rene Westhovens
Journal:  Arthritis Res Ther       Date:  2015-04-09       Impact factor: 5.156

8.  Meta-Analysis: Diagnostic Accuracy of Anti-Carbamylated Protein Antibody for Rheumatoid Arthritis.

Authors:  Liubing Li; Chuiwen Deng; Si Chen; Shulan Zhang; Ziyan Wu; Chaojun Hu; Fengchun Zhang; Yongzhe Li
Journal:  PLoS One       Date:  2016-07-20       Impact factor: 3.240

9.  Long-term outcomes of destructive seronegative (rheumatoid) arthritis - description of four clinical cases.

Authors:  Elena Nikiphorou; Christopher Sjöwall; Pekka Hannonen; Tuomas Rannio; Tuulikki Sokka
Journal:  BMC Musculoskelet Disord       Date:  2016-06-03       Impact factor: 2.362

10.  Comparison of healthcare resource utilization and medical costs between patients with seropositive and seronegative rheumatoid arthritis.

Authors:  Hyoungyoung Kim; Soo-Kyung Cho; Seongmi Choi; Seul Gi Im; Sun-Young Jung; Eun Jin Jang; Yoon-Kyoung Sung
Journal:  Ther Adv Musculoskelet Dis       Date:  2021-06-30       Impact factor: 5.346
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.